Latest Manufacturing Partnerships News

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Papyrus Australia has secured a key milestone under its TBS Mining Contract by executing a board production deal with a Vietnam manufacturer, while raising $325,000 to support commercial scale-up and facility establishment.

Ionic Rare Earths (ASX: IXR) has secured binding agreements to supply critical rare earth oxides to US-based Advanced Magnet Lab, supporting domestic production of permanent magnets for defence applications under a US Defense Logistics Agency contract.

Provaris Energy's proprietary liquified CO2 tank design has cleared a crucial Concept Selection milestone with Yinson, broadening its application beyond floating storage units to carriers and terminals, and advancing its path towards commercialisation.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.

Adisyn’s subsidiary 2D Radar has teamed with Israeli plastics giant Raval to fast-track graphene-enhanced stealth parts for drones, aiming to compress development-to-production timelines from years to months.

Zimi Limited posted 14% revenue growth and landed its biggest project order to date with Homecorp, while slashing operating costs and launching an AI sales agent.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

AdAlta, Oribiotech, and Cell Therapies have inked a Memorandum of Understanding to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and Asia Pacific, aiming to slash costs and boost production speed for CAR-T therapies.

Bioxyne Limited posted a record $21.3 million revenue in Q3 FY26, driven by strong demand for medicinal cannabis and psychedelics. The company secured a manufacturing agreement with Aurora Cannabis and initial orders for GMP psilocybin capsules, reaffirming FY26 guidance.

Electro Optic Systems secures two significant US contracts worth US$12 million for advanced Remote Weapon Systems, while progressing a conditional US$80 million Korean High Energy Laser contract with potential manufacturing shifts.